# Pizarra — PT-pseudo_1185f6a68df0 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_1185f6a68df0
Task: 1

Encounter: Urology - outpatient on 22 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 7.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.329 ng/mL²
  - PSA velocity: 1.09 ng/mL/yr
  - Prior PSA: 5.5 ng/mL
  - Prostate volume: 21.27 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8321669 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Atrial fibrillation
  - Problem list / PMHx: Atrial fibrillation
  - Current medication: apixaban, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 7 ng/mL. PI-RADS 5. PSAD 0.33. Prostate volume 21 mL. csPCa 0.83.

Vitals: weight 101 kg, height 179 cm, BMI 31.5, BP 100/66 mmHg, HR 72 bpm. Smoking: Ex-smoker (22 pack-yr, quit 2021).

Chief complaint: Escalating prostate-specific antigen measurements across a two-year span prompted a recent multiparametric magnetic resonance imaging study.

History: At sixty-three years of age, this retired mechanical engineer first entered clinical evaluation in early 2023 due to a PSA elevation, which has since steadily ascended to 7.0 ng/mL. His urological documentation indicates a prior biopsy bucket of None. Lower urinary tract complaints remain minimal, characterized by slight hesitancy and a modest increase in nocturia, yielding an IPSS score of 7. He explicitly denies hematuria or pelvic discomfort. Physical activity persists through cycling roughly 30 kilometres three times weekly, although advancing joint stiffness necessitates a walking frame for extended distances. He shares his home with his wife, while their grown daughter handles administrative correspondence. His clinical background includes atrial fibrillation, managed with apixaban and metoprolol. A substantial smoking history of 22 pack-years was successfully abandoned in 2021. Aside from receiving a standard influenza vaccination last week and maintaining stable blood pressure readings, he reports feeling generally well, with no complaints of unexplained fatigue or weight reduction.

Physical examination: DRE — texture: smooth and uniformly firm; mobility: unrestricted; asymmetry: absent. General inspection reveals a well-nourished individual in no acute distress. Vital signs demonstrate a regular heart rate of 72 beats per minute alongside a blood pressure of 100/66 mmHg. Peripheral pulses remain palpable, and there is no clinical evidence of peripheral oedema or lymphadenopathy.

Patient info: retired mechanical engineer; Married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 5 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.87 +/- 0.11   (95% CI 0.58-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.05  (few labelled cases resemble this one)
  - 8.1 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=7.0, age=63.0, psad=0.329, dre_ord=0.0, vol=21.27, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the PSA velocity (1.09 ng/mL/yr) and the PSA history (prior PSA of 5.5 ng/mL), which indicate a significant recent rise, against the PI-RADS 5 and the high csPCa probability (0.8321669). It also missed the context provided by the DRE being "Normal" and the specific findings within the retrieved MRI report, which are crucial for interpreting the PI-RADS 5.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy based on a high PI-RADS 5 and high csPCa probability. However, the DRE is reported as "Normal," which contradicts the high suspicion level. Furthermore, the prior does not account for the PSA velocity (1.09 ng/mL/yr) or the prior PSA of 5.5 ng/mL, which suggests a rapid progression that might warrant different management than a stable high PSA. The prior's confidence interval (0.58-1.00) is wide, suggesting high uncertainty, which is exacerbated by the lack of retrieved clinical context.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details focal lesions or specific characteristics of the PI-RADS 5, it would refine the suspicion level.
  <document> PSA history (trend / velocity beyond the headline value) -> If the trend is highly aggressive, it would increase the urgency for biopsy.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the LUTS (IPSS 7) or any prior discussions about the PSA trajectory.
  <document> laboratory results (full panel) -> This could reveal other markers that might influence the risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  Maastricht UMC+ | Radiology | 18 February 2025 | Multiparametric MRI Prostate
  Clinical Indication: A sixty-three-year-old male presents with an upward PSA trajectory (7.0 ng/mL) alongside mild lower urinary tract symptoms. Evaluation aims to exclude clinically significant prostate cancer.
  FINDINGS: The gland occupies a total volume of 21.27 mL. T2-weighted sequences highlight a focal hypointense area measuring roughly 12 x 9 mm within the left peripheral zone at the mid-gland level. Diffusion-weighted imaging shows pronounced signal restriction paired with correspondingly low ADC values. Dynamic contrast-enhanced sequences demonstrate early, focal enhancement confined to the lesion. No extracapsular extension or seminal vesicle invasion is detected. Pelvic lymph nodes appear normal. Skeletal structures show no suspicious osseous lesions.
  IMPRESSION:
  1. PI-RADS 5 lesion located in the left peripheral zone (mid-gland), spanning approximately 12 x 9 mm.
  2. Prostate volume 21.27 mL yielding a PSA density of 0.329 ng/mL/mL.
  3. csPCa predicted probability 0.8321669.

  **psa_trend**
  [{"date": "Mar 2023", "val": 1.3}, {"date": "Feb 2024", "val": 3.0}, {"date": "Feb 2025", "val": 7.0}]

  **previous_notes**
  [{"date": "05 Mar 2023", "author": "Dr. P. van Dijk (GP)", "text": "A routine cardiovascular risk assessment uncovered a prostate-specific antigen level of 4.8 ng/mL, surpassing the age-adjusted local benchmark. Following a discussion on the clinical significance of this elevation, the individual was instructed to schedule a repeat measurement in half a year."}]

  **lab_results**
  [{"name": "PSA", "val": "7.0 ng/mL", "date": "28 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.21 ng/mL", "date": "28 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "17%", "date": "28 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "14.9 g/dL", "date": "28 Jan 2025", "flag": ""}, {"name": "WBC", "val": "7.0 x10^9/L", "date": "28 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "260 x10^9/L", "date": "28 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "77 umol/L", "date": "28 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "28 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "11.1 nmol/L", "date": "28 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "85 U/L", "date": "28 Jan 2025", "flag": ""}, {"name": "LDH", "val": "203 U/L", "date": "28 Jan 2025", "flag": ""}]

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion located in the left peripheral zone (mid-gland), spanning approximately 12 x 9 mm.
  PSA velocity of 1.09 ng/mL/yr, indicating a significant recent rise.
  csPCa predicted probability of 0.8321669.
  The MRI report details a focal lesion with signal restriction and low ADC values.

  AGAINST sampling this patient now:
  DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-grade MRI finding (PI-RADS 5) and the concerning PSA velocity, which aligns with the statistical prior. The contradiction with the normal DRE is noted but the high-risk imaging finding is a strong driver for intervention.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the presence of a PI-RADS 5 lesion (12 x 9 mm) in the left peripheral zone and a concerning PSA velocity of 1.09 ng/mL/yr. This high-grade imaging finding, combined with the rising PSA trend, strongly supports sampling, despite the DRE being reported as normal. The statistical prior favored biopsy, and the retrieved evidence converges on this recommendation.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
